Get the Stockscreener App
4.29
2.50%
-0.11
Lifecore Biomedical Inc stock is traded at $4.29, with a volume of 97,096.
It is down -2.50% in the last 24 hours and down -5.71% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
See More
Previous Close:
$4.40
Open:
$4.41
24h Volume:
97,096
Relative Volume:
0.57
Market Cap:
$162.39M
Revenue:
$147.12M
Net Income/Loss:
$-33.88M
P/E Ratio:
-8.9282
EPS:
-0.4805
Net Cash Flow:
$-13.62M
1W Performance:
-3.81%
1M Performance:
-5.71%
6M Performance:
+7.25%
1Y Performance:
-39.19%
1-Day Range:
$4.21
$4.41
1-Week Range:
$4.21
$4.55
52-Week Range:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.29 | 162.39M | 147.12M | -33.88M | -13.62M | -0.4805 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
472.21 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Sep-04-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
View All
Lifecore Biomedical Inc Stock (LFCR) Latest News
Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR) - Seeking Alpha
Lifecore plans customer meetings in Milan this October - Stock Titan
Lifecore Biomedical to Participate at CPHI Global Conference - GlobeNewswire
Lifecore Strikes Tech Transfer Deal for Commercial Manufacturing of Major Pharma Company Injectable - Contract Pharma
Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product - Quiver Quantitative
A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan
LFCR Q2 2026 Earnings: Narrower Loss of -$0.19 Beats Estimates, Shares Dip 1.35%Revenue Guidance Update - vinanet.vn
Lifecore (LFCR) Results at a Glance: EPS Lands Above Forecast in Latest Trading; Session Move: Shares Rise 0.22% at the CloseEarnings Season Preview - vinanet.vn
Lifecore (LFCR) Earnings Reading: EPS Prints Above Forecast at the Close; After Results: Shares Move 2.42% Down on the DayGuidance Downgrade Alert - vinanet.vn
LFCR | Lifecore Biomedical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Lifecore Biomedical Earnings Call Balances Growth and Strain - TipRanks
Lifecore (LFCR) Quarterly Scorecard: EPS Beats Its Estimate; The Stock Records a 1.83% Increase on the DayROA Comparison - vinanet.vn
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity - Yahoo Finance
Avoiding Lag: Real-Time Signals in (LFCR) Movement - news.stocktradersdaily.com
LFCR Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 16.59% EPS SurpriseAnalyst Coverage Count - vinanet.vn
Lifecore Biomedical (LFCR) Holds Above $4.50 Support as Shares Edge LowerSell Signal Alerts - vinanet.vn
LFCR Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest EncouragementGuidance vs Actual - vinanet.vn
Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer
William Blair Maintains Lifecore Biomedical(LFCR.US) With Buy Rating - Moomoo
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - Stock Traders Daily
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
LFCR: Revenue and profit declined, but cost cuts and new wins support strong long-term growth outlook - TradingView
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Q2 Earnings Call Highlights - MarketBeat
Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - tradingview.com
Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo
Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative
Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView
Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com
Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan
Lifecore Biomedical Reports Financial Results for the - GlobeNewswire
LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Overshadows the QuarterEstimate Dispersion - careplusvn.com
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - MarketBeat
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire
LFCR Q1 2026 Earnings: Significant Earnings Miss Amid Operational ChallengesAnalyst Earnings Estimate - careplusvn.com
Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et
Lifecore Biomedical signs three new customer de... - Pluang
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.46%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):